CAMBRIDGE, MA--(Marketwire -06/14/12)- Molecular Insight Pharmaceuticals, Inc. today announced the presentation of nonclinical and clinical data at the Society of Nuclear Medicine 2012 Annual Meeting held June 9-13 in Miami Beach, Florida. The data were presented in seven oral sessions and five poster presentations and focused on the Company's small molecule approach to targeted radiotherapy and imaging of cancer, with particular emphasis on prostate cancer. These scientific presentations are available on the Company's website: http://www.molecularinsight.com/MolecularMedicine/ScientificPresentations.aspx
In a presentation titled "Small Molecule Inhibitors of Prostate Specific Membrane Antigen (PSMA) for SPECT: Summary of Phase 1 Studies in Patients with Prostate Cancer (PCa)" (Abstract 179), Dr. John W. Babich, President and Chief Scientific Officer, discussed how 123I and 99mTc-labeled small molecule PSMA inhibitors can rapidly detect metastatic prostate cancer in soft tissue and bone with high specificity and clearly visualize sub-centimeter lymph nodes. In this Phase 1 study, 123I-MIP-1072 planar and SPECT imaging were compared with 111In capromab pendetide images in a group of 24 advanced metastatic prostate cancer patients. Standard clinical endpoints of a prior documented prostate cancer diagnosis including clinical outcome, serial PSA levels, and CT and bone scans were used to define truth; biopsy confirmation of lesions detected radiographically was not included in this Phase 1 study. In 67% of subjects, a greater amount of tumor burden was observed by 123I-MIP-1072 imaging than in the same subjects imaged with 111In capromab pendetide. Additionally, there was agreement in 29% of subjects in which the 111In capromab pendetide and 123I-MIP-1072 estimated the same amount of tumor burden. The study also showed that 123I-MIP-1072 identified 20%-25% more subjects with at least one positive lesion than did 111In capromab pendetide. In addition, at the lesion level, upwards of 50% more lesions were identified as positive by 123I-MIP-1072 as compared to 111In capromab pendetide.
Also presented were the results of a separate study comparing the distribution, kinetics, and prostate cancer targeting of 99mTc-MIP-1404 and 99mTc-MIP-1405 in six patients with metastatic cancer and in six normal men. 99mTc- labeled MIP-1404 and MIP-1405 rapidly localized in bone and lymph node metastases as early as 1 hour post injection and both agents cleared rapidly from blood. Both agents identified a greater number of lesions than bone scans and rapidly detected soft tissue prostate cancer lesions including sub-centimeter lymph nodes. Non-significant uptake was seen in the prostate of normal men, though significantly lower urinary activity was seen with 99mTc-MIP-1404 than with 99mTc-MIP-1405. The lower urinary activity allows enhanced visualization of the prostate and lymph nodes in the lower pelvis making 99mTc-MIP-1404 the preferred agent for further development.
"In patients with metastatic prostate cancer, our clinical studies demonstrated that our technetium-99m-labeled compounds, particularly MIP-1404, rapidly localize to lesions in lymph nodes and bone on whole-body imaging as early as 1 hour post injection," noted Dr. Babich. "The study also showed there is a good correlation with bone scans in most subjects, but, in general, more lesions are visualized with 99mTc-MIP-1404 than with bone scan. With an increasing number of new therapies coming to market for the prostate cancer patient, visualizing disease earlier should help physicians make more rapid and informed decisions regarding the sequencing and use of this expanding group of drugs."
Dr. Babich continued, "Since our studies have demonstrated that 99mTc-MIP-1404 has less urinary excretion, and since better visualization of the prostate and surrounding lymph nodes is crucial in the imaging of prostate cancer, the Company plans to initiate a multi-center international Phase 2 clinical trial in high risk prostate cancer patients undergoing a prostatectomy. The aim of this trial will be to validate 99mTc-MIP-1404 uptake with the presence of prostate cancer in the prostate and lymph nodes as determined by histopathology. The Phase 2 trial is set to begin in the third quarter of 2012."
A second presentation titled, "[131I]MIP-1466, A Small Molecule Prostate-Specific Membrane Antigen (PSMA) Inhibitor for Targeted Radiotherapy of Prostate Cancer (PCa)" (Abstract 170), was delivered by Dr. Shawn M. Hillier, Associate Director, Biology. In this study 123I-MIP-1095, a high affinity ligand for PSMA in prostate cancer, has been shown to localize to radiologically-confirmed metastatic prostate cancer in men. That high expression of PSMA in prostate cancer led to the evaluation of the 131I analog of MIP-1095 (currently identified as MIP-1466) for therapeutic efficacy in a mouse tumor model of human prostate cancer. It was shown that 131 I-MIP-1466 dose dependently inhibited the growth of tumor xenografts in a PSMA specific manner at 131I doses that are clinically relevant. These data support clinical investigation of 131I-MIP-1466 as a targeted radiotherapeutic for the treatment of prostate cancer in men.
From now on, the compound currently identified as MIP-1466 will be known as 131I-MIP-1095. 131 I-MIP-1095 is structurally identical to 123I-MIP-1095 which was previously studied in humans for imaging prostate cancer. It is anticipated that an IND application for 131I-MIP-1095 will be filed with the U.S. Food and Drug Administration in the fourth quarter of this year, and that a Phase 1 dose escalation clinical trial will begin in the first quarter of 2013.
A third presentation titled, "Development of a Simple Kit for Tc-99m-MIP-1404, a Single Amino Acid Chelate (SAACII) Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer" (Abstract 523), was given by Director of Radiochemistry and Production, Dr. Kevin P. Maresca. He reported on the development of a simple and efficient radiolabeling kit that could eventually be used to prepare 99mTc-MIP-1404 in radiopharmacies around the world for clinical studies and beyond. Optimization of the radiolabeling reaction conditions (time, temperature and concentration) of the final product was described. Radiochemical yield, radiochemical purity and specific activity were determined by HPLC analysis.
Dr. Maresca reported that the kit preparation method was shown to be robust and tolerant to a broad range of concentrations and volumes. The simple kit also allows the production of 99mTc-MIP-1404 in high radiochemical yield, radiochemical purity and specific activity. 99mTc-MIP-1404 demonstrated excellent radiochemical stability of greater than 90% after more than 24 hours at room temperature. Furthermore, this simple kit procedure has produced sterile, safe and high quality formulations of the 99mTc-MIP-1404 that maintain PSMA binding affinity and allows for vivid diagnostic images of prostate cancer as demonstrated in early clinical experience.
About Molecular Insight Pharmaceuticals, Inc. Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company focused on critical unmet diagnosis and therapeutic needs of the prostate cancer patient. The Company is targeting the development of a proprietary small molecule platform to improve detection and visualization of primary and metastatic prostate cancer and to provide a novel systemic radiotherapy for relapsed and metastatic prostate cancer. For further information, please visit the Company's website: http://www.molecularinsight.com.
See the original post here:
- Podcast 9 Athens part 3 and news - November 8th, 2009 [November 8th, 2009]
- Podcast 10 Athens part 4 - November 8th, 2009 [November 8th, 2009]
- Podcast 11 Athens Part 5 - November 8th, 2009 [November 8th, 2009]
- Episode 12 Cardiac Nuclear Medicine in the UK - November 8th, 2009 [November 8th, 2009]
- Podcast 13 Choline PET and prostate cancer - November 8th, 2009 [November 8th, 2009]
- Episode14 ED function and Dysponea - November 8th, 2009 [November 8th, 2009]
- ep 15 Collimator Choice and Reconstruction algorithm - November 8th, 2009 [November 8th, 2009]
- Episode 16 Dr Strauss on vulnerable plaque - November 8th, 2009 [November 8th, 2009]
- Episode17 Chemical Stress - November 8th, 2009 [November 8th, 2009]
- Episode 18 Myocardial Perfusion Imaging and Diabetes - November 8th, 2009 [November 8th, 2009]
- Episode 19 The INSPIRE trial - November 8th, 2009 [November 8th, 2009]
- 20 Dual isotope with a difference - November 8th, 2009 [November 8th, 2009]
- Episode 21 The real effect of stress - November 8th, 2009 [November 8th, 2009]
- Episode 22 D-SPECT - November 8th, 2009 [November 8th, 2009]
- Episode 23 VQ Reprise - November 8th, 2009 [November 8th, 2009]
- Episode 24 Hepatobiliary Nuclear Medicine - November 8th, 2009 [November 8th, 2009]
- Episode 25 Sleep Apnea - November 8th, 2009 [November 8th, 2009]
- Episode 26 Imaging Post Traumatic Stress Disorder - November 8th, 2009 [November 8th, 2009]
- Episode 27 Cardiac Stem Cells - November 8th, 2009 [November 8th, 2009]
- Episode 28 Molly Supply - November 8th, 2009 [November 8th, 2009]
- Episode 29 Melanoma therapy interview with Dr Ekaterina Dadachova - November 8th, 2009 [November 8th, 2009]
- Episode 30 Viral Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 31 breast radiotherapy using radioisotopes - November 8th, 2009 [November 8th, 2009]
- Episode 32 news from snm - November 8th, 2009 [November 8th, 2009]
- Episode 33 EBV Imaging and Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 34 Dr Lele SNM India 2009 - December 14th, 2009 [December 14th, 2009]
- Episode 35 Dr Andrew Scott from the Ludwig institute - January 10th, 2010 [January 10th, 2010]
- Episode 36 CardiArc - February 25th, 2010 [February 25th, 2010]
- Episode 37 Dr Modder Radiosynoviorthesis (Radiation Synovectomy) - March 31st, 2010 [March 31st, 2010]
- Episode 38 Indian Nuclear Medicine With Dr Malhotra and Dr Krishna - May 28th, 2010 [May 28th, 2010]
- Episode 39 Prof Ora Israel The Utility of Hybrid Imaging - July 13th, 2010 [July 13th, 2010]
- Episode 40 New V/Q SPECT developments - October 11th, 2010 [October 11th, 2010]
- Episode 41 scintimun - February 14th, 2011 [February 14th, 2011]
- Episode 42 Radio-Isotope Supply into the future - March 6th, 2011 [March 6th, 2011]
- Podcast 4: DNA therapy - April 24th, 2011 [April 24th, 2011]
- Sorry about the delay a new podcast will be out soon! - April 24th, 2011 [April 24th, 2011]
- Podcast 5 Flash 3D - April 24th, 2011 [April 24th, 2011]
- Podcast 6 Affibody - April 24th, 2011 [April 24th, 2011]
- Podcast 7 EANM 2006 Athens Part 1 - April 24th, 2011 [April 24th, 2011]
- Podcast 8 Athens Part 2 - April 24th, 2011 [April 24th, 2011]
- Episode 43 Rapidscan Part 1, 720P high quality video version - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Ipod quality video - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Audio version - May 1st, 2011 [May 1st, 2011]
- Episode 45 Mummies with cardiovascular disease video - May 21st, 2011 [May 21st, 2011]
- Episode 45 Mummies with cardiovascular disease audio edition - May 21st, 2011 [May 21st, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective - August 7th, 2011 [August 7th, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective audio version - August 7th, 2011 [August 7th, 2011]
- Episode 47 Cardiac Image Fusion With Dr Kaufmann - September 18th, 2011 [September 18th, 2011]
- Episode 47 Cardiac Fusion with Dr Kaufmann video version - September 18th, 2011 [September 18th, 2011]
- Dear Steve, I am and many more like me are your one more thing. - October 9th, 2011 [October 9th, 2011]
- EPISODE 48 PET MRI camera from Siemens with Dr Georgi audio - October 23rd, 2011 [October 23rd, 2011]
- EPISODE 48 PET MRI camera from Siemens Dr Georgi video - October 23rd, 2011 [October 23rd, 2011]
- Silicon Biosystems to Present Single-Circulating Tumor Cell Molecular Characterization at the Fourth World CTC Summit - April 25th, 2012 [April 25th, 2012]
- Leukaemia cells have a remembrance of things past - April 25th, 2012 [April 25th, 2012]
- Technologist Education Requirements Can Help Cut Repeat Scans - April 25th, 2012 [April 25th, 2012]
- HKU Collaborative Research Discovers A Novel Molecular Mechanism Of A New Anti-HIV-1 Drug Candidate - April 25th, 2012 [April 25th, 2012]
- Focal Segmental Glomerulosclerosis and the Nephrotic Syndrome - Part 1 Clinical - Video - May 4th, 2012 [May 4th, 2012]
- Electro-Medicine : Biological Physics - The Molecular Basis of Alzheimers Disease - Video - May 4th, 2012 [May 4th, 2012]
- osdd heterocyclic compounds and molecular medicines - Video - May 4th, 2012 [May 4th, 2012]
- Molecule to Medicine: The Biomarker Frontier - Video - May 4th, 2012 [May 4th, 2012]
- Fulfilling the Promise of Molecular Medicine in a Developmental Brain Disorder - Video - May 4th, 2012 [May 4th, 2012]
- Focus on Stefanie Dimmeler - Video - May 4th, 2012 [May 4th, 2012]
- Dundee - May 4th, 2012 [May 4th, 2012]
- Nanotechnology In Medicine: Huge Potential, But What Are The Risks? - May 5th, 2012 [May 5th, 2012]
- Cutting Edge Technology Coming To DMH - May 5th, 2012 [May 5th, 2012]
- This Week in Experimental and Molecular Pathology - May 5th, 2012 [May 5th, 2012]
- Researchers' discovery offers hope for cancer, heart disease miracle drugs - May 7th, 2012 [May 7th, 2012]
- Penn State student Zachary Hostetler from Garnet Valley is being honored as a student marshal - May 7th, 2012 [May 7th, 2012]
- NCKU Student Wins Prestigious Award for Anti-Cancer Research - May 10th, 2012 [May 10th, 2012]
- In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers ... - May 10th, 2012 [May 10th, 2012]
- Pitt team uses genomics to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- Genomics used to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- 2 molecular biologists get $500K medical prize - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists share $500K medical prize - May 13th, 2012 [May 13th, 2012]
- Lab21 Unveils New Molecular Analysis Services at Greenville Site - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists from NYC to share $500K medical prize for pioneering research on cells - May 13th, 2012 [May 13th, 2012]
- Two Molecular Biologists Get $500K Medical Prize - May 13th, 2012 [May 13th, 2012]
- Pair of molecular biologists receive Albany Medical Center Prize - May 13th, 2012 [May 13th, 2012]
- CNIO scientists successfully test the first gene therapy against aging-associated decline - May 16th, 2012 [May 16th, 2012]
- Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine' - May 16th, 2012 [May 16th, 2012]